New Drugs, Drug Therapies and Patient Education Changing Managed Care, Hospitals and Health Care Delivery

Hospital Admissions, Lengths-of-Stays Down; Prescription Drugs, Managed Care

Enrollments Up, According to 15-Year Study of Health Care Benchmarks



Apr 23, 2001, 01:00 ET from Aventis Pharmaceuticals, Inc.

    BRIDGEWATER, N.J., April 23 /PRNewswire Interactive News Release/ -- New
 drugs, the increasing use of drug therapies and the emergence of consumer
 health care education has profoundly affected health care delivery, according
 to a 15-year study of health care industry benchmarks.
     The surge in the use of prescription drugs has been accompanied by
 declining hospital admission rates and shorter lengths-of-stay, according to
 Managed Care Trends 2000, a 32-page study of healthcare industry benchmarks.
     "Hospitalization is the greatest single component of cost in any episode
 of illness," said Joel Shalowitz, M.D., MBA, Director of the Health Industry
 Management program at Northwestern University's J.L. Kellogg Graduate School
 of Management.  "Managed care's main effect on hospitalization has been a
 reduction in discretionary admissions."
 
     According to the study:
     -- The average number of prescriptions per commercial HMO member per year
        increased 43 percent between 1988 and 1998;
     -- Hospital admissions per 1,000 commercial HMO members fell 22 percent
        between 1990 and 1998;
     -- The number of days per 1,000 members spent in the hospital declined 46
        percent during the same time period.
 
     (*All statistics are published in Aventis Pharmaceuticals Managed Care
 Trends Digest 2000)
 
     Factors driving the surge in the use of pharmaceuticals include the
 introduction of new drugs, new uses for existing drugs and an increased
 emphasis on patient education, said John Rodgers, Director of Pharmacy at
 Independent Health Association, a 400,000-member HMO in Buffalo, N.Y.
     "We've discovered new drugs and new applications for existing drugs, all
 to the benefit of the patient," Rodgers said.  "We're prescribing more drugs
 because they happen to be the best therapy for any number of conditions."
     In addition to new drugs, advances in detection, diagnosis and treatment
 of diseases have changed approaches to relatively common conditions that were
 previously untreated, under-treated or required hospitalization.  Those
 conditions include asthma, diabetes, high cholesterol and hypertension.
     Well-managed and highly profitable hospitals will continue to grow because
 they have invested in technologies that will maintain their high performance.
 Meanwhile, many under-performing hospitals have been shielded from hard times
 by the surging economy -- their investment portfolios have been doing well,
 but their operating margins are poor, Shalowitz said.
 
     Other highlights from Managed Care Trends 2000:
     -- Enrollment in managed care plans nationwide grew from 12.5 million in
        1983 to 105.3 million in 1998, making it the health care coverage of
        choice for most U.S. employers and their workers.
     -- The number of point-of-service enrollees and open-ended plans increased
        more than 10 percent from 1994 to 1998, due to their added flexibility
        and wider choice.  These plans now account for more members than all
        other types of managed care plans.
     -- The number of PPO plans that included a managed pharmacy program surged
        from 37 percent in 1990 to 80 percent in 1998.
     -- The total number of Medicare beneficiaries enrolled in HMO plans
        climbed from 1.4 million in 1986 to 6.5 million in 1998.  In 1998, 17.3
        percent of the nation's 37.6 million Medicare beneficiaries were
        enrolled in HMOs.
 
     (*All statistics are published in Aventis Pharmaceuticals Managed Care
 Trends Digest 2000)
 
     Sponsored by Aventis Pharmaceuticals, Inc., Managed Care Trends 2000 is a
 new, special edition of the Aventis Pharmaceuticals Managed Care Digest
 Series(TM), a 15-year series of health care data collected by a partnership of
 SMG Marketing Group, the American Medical Group Association and the Medical
 Group Management Association.
     Aventis Pharmaceuticals conducts the U.S. business of Aventis Pharma AG.
 With headquarters in Bridgewater, N.J., Aventis Pharmaceuticals focuses its
 activities on important therapeutic areas such as cardiology, oncology,
 anti-infectives, arthritis, allergy and respiratory, diabetes and central
 nervous system.
     Aventis Pharma AG is the pharmaceutical company of Aventis S.A.
 (NYSE:   AVE).  Aventis Pharma is dedicated to treating and preventing human
 disease through the discovery, development, manufacture and sale of innovative
 pharmaceutical products aimed at fulfilling unmet medical needs.  The
 corporate headquarters of Aventis Pharma is in Frankfurt, Germany.  Aventis
 Pharma is comprised of Aventis Pasteur, a world leader in vaccines,
 headquartered in Lyon, France, and Aventis Behring, a world leader in
 therapeutic proteins, headquartered in King of Prussia, Pa.
     Aventis S.A., a world leader in pharmaceuticals and agriculture, is
 headquartered in Strasbourg, France.  The company employs approximately 95,000
 people in more than 120 countries.  Aventis was launched in December 1999
 through the merger of Hoechst AG and Rhone-Poulenc S.A.
     To receive a copy of this release of any recent release via fax, call
 Aventis Pharmaceuticals' automated news fax line at 800/556-7422 or
 816/966-3434.
 
     Statements in this news release other than historical information are
 forward-looking statements subject to risks and uncertainties.  Actual results
 could differ materially depending on factors such as the availability of
 resources, the timing and effects of regulatory actions, the strength of
 competition, the outcome of litigation and the effectiveness of patent
 protection.  Additional information regarding risks and uncertainties is set
 forth in the current Annual Report on Form 20-F of Aventis on file with the
 Securities and Exchange Commission.
     For more information visit www.managedcaredigest.com .
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X42760277
 
 

SOURCE Aventis Pharmaceuticals, Inc.
    BRIDGEWATER, N.J., April 23 /PRNewswire Interactive News Release/ -- New
 drugs, the increasing use of drug therapies and the emergence of consumer
 health care education has profoundly affected health care delivery, according
 to a 15-year study of health care industry benchmarks.
     The surge in the use of prescription drugs has been accompanied by
 declining hospital admission rates and shorter lengths-of-stay, according to
 Managed Care Trends 2000, a 32-page study of healthcare industry benchmarks.
     "Hospitalization is the greatest single component of cost in any episode
 of illness," said Joel Shalowitz, M.D., MBA, Director of the Health Industry
 Management program at Northwestern University's J.L. Kellogg Graduate School
 of Management.  "Managed care's main effect on hospitalization has been a
 reduction in discretionary admissions."
 
     According to the study:
     -- The average number of prescriptions per commercial HMO member per year
        increased 43 percent between 1988 and 1998;
     -- Hospital admissions per 1,000 commercial HMO members fell 22 percent
        between 1990 and 1998;
     -- The number of days per 1,000 members spent in the hospital declined 46
        percent during the same time period.
 
     (*All statistics are published in Aventis Pharmaceuticals Managed Care
 Trends Digest 2000)
 
     Factors driving the surge in the use of pharmaceuticals include the
 introduction of new drugs, new uses for existing drugs and an increased
 emphasis on patient education, said John Rodgers, Director of Pharmacy at
 Independent Health Association, a 400,000-member HMO in Buffalo, N.Y.
     "We've discovered new drugs and new applications for existing drugs, all
 to the benefit of the patient," Rodgers said.  "We're prescribing more drugs
 because they happen to be the best therapy for any number of conditions."
     In addition to new drugs, advances in detection, diagnosis and treatment
 of diseases have changed approaches to relatively common conditions that were
 previously untreated, under-treated or required hospitalization.  Those
 conditions include asthma, diabetes, high cholesterol and hypertension.
     Well-managed and highly profitable hospitals will continue to grow because
 they have invested in technologies that will maintain their high performance.
 Meanwhile, many under-performing hospitals have been shielded from hard times
 by the surging economy -- their investment portfolios have been doing well,
 but their operating margins are poor, Shalowitz said.
 
     Other highlights from Managed Care Trends 2000:
     -- Enrollment in managed care plans nationwide grew from 12.5 million in
        1983 to 105.3 million in 1998, making it the health care coverage of
        choice for most U.S. employers and their workers.
     -- The number of point-of-service enrollees and open-ended plans increased
        more than 10 percent from 1994 to 1998, due to their added flexibility
        and wider choice.  These plans now account for more members than all
        other types of managed care plans.
     -- The number of PPO plans that included a managed pharmacy program surged
        from 37 percent in 1990 to 80 percent in 1998.
     -- The total number of Medicare beneficiaries enrolled in HMO plans
        climbed from 1.4 million in 1986 to 6.5 million in 1998.  In 1998, 17.3
        percent of the nation's 37.6 million Medicare beneficiaries were
        enrolled in HMOs.
 
     (*All statistics are published in Aventis Pharmaceuticals Managed Care
 Trends Digest 2000)
 
     Sponsored by Aventis Pharmaceuticals, Inc., Managed Care Trends 2000 is a
 new, special edition of the Aventis Pharmaceuticals Managed Care Digest
 Series(TM), a 15-year series of health care data collected by a partnership of
 SMG Marketing Group, the American Medical Group Association and the Medical
 Group Management Association.
     Aventis Pharmaceuticals conducts the U.S. business of Aventis Pharma AG.
 With headquarters in Bridgewater, N.J., Aventis Pharmaceuticals focuses its
 activities on important therapeutic areas such as cardiology, oncology,
 anti-infectives, arthritis, allergy and respiratory, diabetes and central
 nervous system.
     Aventis Pharma AG is the pharmaceutical company of Aventis S.A.
 (NYSE:   AVE).  Aventis Pharma is dedicated to treating and preventing human
 disease through the discovery, development, manufacture and sale of innovative
 pharmaceutical products aimed at fulfilling unmet medical needs.  The
 corporate headquarters of Aventis Pharma is in Frankfurt, Germany.  Aventis
 Pharma is comprised of Aventis Pasteur, a world leader in vaccines,
 headquartered in Lyon, France, and Aventis Behring, a world leader in
 therapeutic proteins, headquartered in King of Prussia, Pa.
     Aventis S.A., a world leader in pharmaceuticals and agriculture, is
 headquartered in Strasbourg, France.  The company employs approximately 95,000
 people in more than 120 countries.  Aventis was launched in December 1999
 through the merger of Hoechst AG and Rhone-Poulenc S.A.
     To receive a copy of this release of any recent release via fax, call
 Aventis Pharmaceuticals' automated news fax line at 800/556-7422 or
 816/966-3434.
 
     Statements in this news release other than historical information are
 forward-looking statements subject to risks and uncertainties.  Actual results
 could differ materially depending on factors such as the availability of
 resources, the timing and effects of regulatory actions, the strength of
 competition, the outcome of litigation and the effectiveness of patent
 protection.  Additional information regarding risks and uncertainties is set
 forth in the current Annual Report on Form 20-F of Aventis on file with the
 Securities and Exchange Commission.
     For more information visit www.managedcaredigest.com .
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X42760277
 
 SOURCE  Aventis Pharmaceuticals, Inc.